Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE(-/-) mice.
Tirzepatide, the dual GIP/GLP-1 receptor agonist, just made a splash in vascular research. A team out of Valencia put this peptide to the test in ApoE knockout mice, the go-to model for studying abdominal aortic aneurysms (AAA). Why does it matter? Endothelial dysfunction is the first domino in the chain that leads to aneurysms. If you can stop that, you might sidestep a deadly problem.
Pharmacol Res
by Gómez-Martín Á, Marques P, Arce-Recatalá C et al.
“Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE(-/-) mice. Gómez-Martín Á(1), Marques P(2), Arce-Recatalá C(1), Vea Á(1), Domingo E(1), Alabadi B(3), Real JT(4), Sanz MJ(5), Piqueras L(6). Author information: (1)Department of Pharmacology, University of Valencia, Valencia, Spain; Institute of Health Research-INCLIVA, Valencia, Spain. (2)Department of Pharmacology, University of Valencia, Valencia, Spain; Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain; CIBEREHD-Spanish Biomedical Research Center in Hepatic and Digestive Diseases, Carlos III Health Institute (ISCIII), Madrid, Spain. (3)Endocrinology and Nutrition Service, University Clinic Hospital of Valencia, Valencia, Spain; CIBERDEM-Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders, Carlos III Health Institute (ISCIII), Madrid, Spain. (4)Endocrinology and Nutrition Service, University Clinic Hospital of Valencia, Valencia, Spain; CIBERDEM-Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders, Carlos III Health Institute (ISCIII), Madrid, Spain. Electronic address: jose.t.real@uv.es. (5)Department of Pharmacology, University of Valencia, Valencia, Spain; Institute of Health Research-INCLIVA, Valencia, Spain; CIBERDEM-Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders, Carlos III Health Institute (ISCIII), Madrid, Spain. Electronic address: maria.j.sanz@uv.es. (6)Department of Pharmacology, University of Valencia, Valencia, Spain; Institute of Health Research-INCLIVA, Valencia, Spain; CIBERDEM-Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders, Carlos III Health Institute (ISCIII), Madrid, Spain. Electronic address: laura.piqueras@uv.es. Endothelial dysfunction is a critical initiating event in abdominal aortic aneurysm (AAA), a condition posing a high risk of a fatal rupture. Dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists have emerged as potent treatments for diabetes and obesity, with clinical evidence suggesting broader cardiovascular benefits. However, the direct impact of tirzepatide (dual GLP-1R/GIPR agonist) on endothelial dysfunction and AAA pathogenesis remains poorly understood. We investigated the effects of dual GLP-1R/GIPR agonism on endothelial dysfunction and AAA development. We employed parallel-plate flow chamber assays to evaluate the effects of tirzepatide on TNFα-induced leukocyte-endothelium interactions. Expression of GLP-1R, GIPR, adhesion molecules (VCAM-1 and ICAM-1), and NF-κB activation was quantified using immunofluorescence and western blotting. The in vivo efficacy of tirzepatide was assessed using an angiotensin-II-infused apoE-/- mouse model of AAA. GLP-1R and GIPR were expressed in human endothelial cells and murine suprarenal aortas. Tirzepatide significantly attenuated TNFα-induced leukocyte-endothelium interactions, downregulated VCAM-1/ICAM-1/CX3CL1 expression, and inhibited the mRNA expression and generation of MCP-1 and RANTES. Mechanistically, these effects were driven by the suppression of NF-κB activation. Chronic subcutaneous administration of tirzepatide over 28 days significantly limited suprarenal aortic expansion and reduced AAA incidence in Ang-II-infused mice. This vasoprotective effect was characterized by preserved elastin integrity, reduced neovessel formation, and diminished macrophage accumulation within the aneurysmal wall. Dual GLP-1R/GIPR agonism mitigates endothelial dysfunction and suppresses inflammatory pathways driving AAA progression. These findings position tirzepatide as a promising therapeutic strategy for the prevention of vascular remodeling and AAA development. Copyright © 2026. Published by Elsevier Ltd. Conflict of interest statement: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.”
Here’s the gist: researchers used tirzepatide to see if it could slow down or prevent aneurysm formation triggered by angiotensin II—a classic AAA driver in mice. They ran a battery of assays, from flow chamber tests looking at how white blood cells stick to blood vessels, to deep molecular dives with western blots and immunofluorescence.
Key findings:
Tirzepatide cut down inflammatory white blood cell interactions with the endothelium.
It suppressed VCAM-1, ICAM-1, and other key adhesion molecules.
The peptide also hit the brakes on NF-κB, a notorious inflammation switch.
After 28 days, mice on tirzepatide had less aortic expansion and fewer aneurysms.
The vessel walls were in better shape—less inflammation, stronger elastin, and fewer new vessels forming.
The authors say this is about more than blood sugar. Dual GLP-1R/GIPR agonism with tirzepatide could help prevent the vascular remodeling that leads to AAA. Big deal for peptide researchers looking at new indications.
If you’re tracking vascular or metabolic research compounds, keep tirzepatide on your radar. Get the full details on tirzepatide or check the vendor directory if you’re sourcing for your next project.
Bottom line: tirzepatide isn’t just for metabolic studies. It’s showing potential in vascular protection too.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.